Contact:
sales@biotechnologyforums.com to feature here

Thread Rating:
  • 0 Vote(s) - 0 Average
  • 1
  • 2
  • 3
  • 4
  • 5
Actelion Plans on Buying Out Ceptaris for $250 Million
#1
Actelion is a reputed Biotech firm located at Basel, Switzerland. The firm is famous for being the pioneers in the area regarding endothelian receptor antagonists. The first product successfully manufactured by the firm was an endothelian receptor antagonist. Actelion was initially financed and supported by venture capital along with companies such as HealthCap and Sofinnova. Actelion is a specialist when it comes to orphan diseases and this is a tricky research prospect mainly due to the fact that investors often do not choose to invest in such companies due to fear of low ROI.

Orphan Diseases and Their Types

However, this is a serious problem for patients affected by orphan diseases and as a result Actelion CEO, Jean Paul Clozel decided to work on such rare diseases. Orphan diseases are known to affect children and Actelion works on research on such diseases and their cures.
Actelion currently operates out of 28 countries around the globe namely Canada, Japan, Australia, Brazil, Switzerland and a few other European countries such as France, and the United Kingdom. The Actelion Endothelin Research Award program was started back in 2006 with the aim of supporting selective research programs. Actelion is currently known for working on ten important drugs, 3 of which are at their final stages of research.

Traceleer is known to work on the enhancement of pulmonary arterial hypertension and is the first from Actelion. Pulmonary arterial hypertension is a known but rare chronic disease which is life threatening. It severely affects the heart and lungs and disrupts the functionalities. Zavesca is the only oral treatment at the moment for patients suffering from Gaucher disease.

Ventavis is the third drug from Actelion aimed at working on pulmonary arterial hypertension while Veletri is a long time cure for scleroderma spectrum diseases. Actelion is a reputed company and the research and development team is fairly renowned in this field of operation. The company currently employs 2,467 people in research, development marketing and sales and has posted sales equivalent to 1,929 million CHF. Actelion started trading as a member of the Swiss Market Index since September 2006.

Stepping on The Growing Cloth

Actelion plans on making huge profits in the financial quarter of 2014 – 2015 if its new lung and heart drugs are better received in the market in the meantime. Chief Financial Officer Andrew Oakley recently said in an interview that there is room for enhancement in sales and the company is working on improving the current batch of drugs. Actelion claims that the company is planning on crossing eight digits in terms of earnings by the end of the year.

The growth picked up back in 2012 and is continuing well into 2013. As a result the company is quite happy with the returns and is planning big for the time ahead. Actelion recently received a boost from the market as its lung and heart drug was well received in the market. Opsumit replaced the best selling Tracleer recently and the results obtained were outstanding. This is also a revolutionary find as Tracleer accounts for close to 87 percent of the total sales recorded at Actelion.

Actelion received quite a few awards during the course of its innovations and the Prix Hermès de l'innovation or the Hermès Award for Innovation, it received in 2011 is the most prestigious of them all. Actelion is a think tank of scientists and some of the greatest minds from around the world come together to work jointly in projects. Actelion plans on enhancing values through its vast knowledge in the field of pulmonary arterial hypertension therapy.

Best Investments for a Cause

Actelion plans on chasing best quality infrastructure along with the best possible research and the plans are commercially viable too. A completely balanced environment is created within the laboratories and this helps preserve the viability of the drugs. Seeking out licenses to coming up with new drugs to maximize production. Actelion is also a market leader in terms of marketing strategies and the company has huge followers and record huge sales while securing huge profit margins due to its innovations.

Actelion works towards promoting a better environment for work, encouraging proactive identification while assessing the risks involved. This is a varied task which needs constant monitoring. Saving lives is the major concern at Actelion and that is the common target people try to achieve at work. A committed work power is also what distinguishes Actelion from the other Biotechnology companies in Switzerland.

The list of patients at Actelion is quite high and most of them have been worked on carefully. Actelion has taken quite some time to reach where it is actually at the moment Actelion recently plans purchasing Ceptaris Therapeutics for close to $250 million. This is a confirmed report especially after the latest developments from Actelion seem to be making quite an impact in the market.

FDA seems to have been a problem with Actelion and their investment plans in the past although no such issues have surfaced within the past couple of years. Actelion wants to build up a formidable reputation and is hence working towards achieving the same. Actelion is known especially for its ability to work on exclusively rare diseases and as a result the investors are willing to work hard.

The company also plans on working on its portfolio apart from the PAH franchise and the company wants to continue working on its rare disease agenda. Orphan diseases are a source of trouble and cause massive damages to certain parts of the body. The heart and lungs are the primary target areas which needs special attention. Actelion has received close to $10 Million in terms of investment within the past few days.

Even though this is not much it is sufficient to keep current projects on track. Needs of the patients need to be fulfilled first and that is the precise course of action Actelion has taken at the moment. Cepatris needed to be bailed out while Actelion needed a new partnership. This as a result made it easy for both sides. The T Cell lymphoma is the final drug that Actelion is currently working on.
Like Post Reply
  




Users browsing this thread:
1 Guest(s)

Actelion Plans on Buying Out Ceptaris for $250 Million00